Tempus CRC Surveillance Study for Colorectal Cancer
This observational study is looking at people with colorectal cancer (CRC) to understand how a blood test called ctDNA biomarker profiling can help monitor their disease. You might be able to join if you have known or suspected colorectal cancer (stages I to IVA) and are planning to have or have already had surgery to remove the cancer. The study will follow participants to see how long they live without their cancer coming back (recurrence-free survival) over two years. The current recruitment status is unclear.
- Study design
- This is an observational study involving 300 participants. It is not a treatment study, but rather observes participants alongside their standard care.
- What's involved
- You would need to provide additional blood samples during your routine follow-up visits after surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for two years to measure recurrence-free survival.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
At a glance
Conditions
Where it's being run
20 sites across 12 statesStudy leadership
- Kristiyana Kaneva, MD, MS · PRINCIPAL_INVESTIGATOR · Tempus AI, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Recurrence-Free Survival2 years
Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death